$CRBU

Caribou Biosciences, a biotech co-founded by Jennifer Doudna, is halting its off-the-shelf CAR-T therapies (vispa-cel for lymphoma, CB-011 for myeloma) due to funding issues for a phase 3 trial. The company will reduce its workforce and explore strategic options. Caribou had $113.8M in cash as of June 30, but cited a challenging financing environment for donor-derived CAR-T therapies.

Vaxcyte reported positive Phase III data for its pneumococcal vaccine. Caribou Biosciences halted its CAR-T program due to funding issues. Argenx discontinued Vyvgart for Sjögren's treatment. Viatris agreed to acquire Pacira Biosciences for $1.65 billion.

Caribou Biosciences (CRBU) is exploring strategic alternatives, including a potential sale, and will discontinue two CAR-T therapy programs. Viatris (VTRS) agreed to acquire Pacira BioSciences for $1.65B. Uber (UBER) will buy ezCater for $2.3B. Skydance (SKYD) completed its acquisition of Warner Bros. Discovery (WBD). True Food Kitchen filed for Chapter 11 bankruptcy.

Roche, Novartis, Pfizer, and Eli Lilly received FDA approvals for their drugs. Lupin and Lipocine also gained regulatory nods. Caribou Biosciences plans to cut workforce and discontinue programs. Several biopharma companies announced deals and partnerships. Stock prices for mentioned companies varied.

Caribou Biosciences, a biotech co-founded by CRISPR pioneer Jennifer Doudna, is exploring strategic alternatives, including a reverse merger or acquisition, due to challenging financing conditions. The company has $114M in cash and has hired Wedbush Securities as its financial advisor. Analysts suggest a reverse merger or acquisition by Tang Capital as potential outcomes.

Argenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.

Caribou Biosciences' average stock price target increased from $10 to $11 by 5 analysts, with a range of $1 to $32. This implies an 869% upside from the Oct. 6 closing price. The consensus rating remains 'Buy', with 3 Buys and 2 Holds.

Caribou Biosciences is halting its CRISPR-based CAR-T cancer therapy research and laying off staff due to funding challenges. The company will explore strategic alternatives, including mergers or acquisitions. Its shares have significantly declined since their 2021 peak. According to the CEO, the decision is not due to a lack of belief in the therapies' potential.

Caribou Biosciences, a biotech developing off-the-shelf CAR-T cell therapies, will discontinue its pipeline and lay off employees, citing shifting investor interest towards in vivo approaches. The company is exploring exit strategies, including mergers or acquisitions. Caribou's board attributes the decision to the current financing environment for allogeneic CAR-T therapies. The company had 97 employees as of February 2026, with substantial layoffs planned.

Constellation Brands (STZ) shares fell 5.1% in pre-market trading despite beating Q2 earnings and sales estimates, reporting $3.74 EPS and $2.633B revenue. The company also announced the acquisition of SpikedAde. Caribou Biosciences (CRBU) shares dropped 35.7% after exploring strategic alternatives and discontinuing two cell therapy programs.